Surface modification with functionally active heparin.

J Riesenfeld; P Olsson; J Sanchez; T E Mollnes

Home/Archive/PubMed

PubMed · 10155375

Surface modification with functionally active heparin.

J Riesenfeld·P Olsson·J Sanchez·T E Mollnes

View original source ↗Export metadata ↓

Abstract

Efforts to improve the blood compatibility of artificial materials have involved coating the surfaces with heparin. However, the anticoagulation activity of heparin is based on its binding to antithrombin, and if the specific structure involved in this interaction is compromised by the coating procedure, then the activity is lost. Surface modification with end-point-immobilized heparin has been found to be successful in inhibiting coagulation factors and minimizing complement activation.

Explore related subjects

Antithrombin III Blood Coagulation Complement Activation Equipment and Supplies Heparin Humans Materials Testing Protein Binding Surface Properties Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

J Riesenfeld, P Olsson, J Sanchez, T E Mollnes. 1995. Surface modification with functionally active heparin.. https://pubmed.ncbi.nlm.nih.gov/10155375/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2000

Inhibition of antithrombin by protein SV-IV normalizes the coagulation of hemophilic blood.

The aim of the study was to evaluate the effect of the protein Seminal Vesicle Protein No. 4 (SV-IV), a potent inhibitor of antithrombin III (antithrombin), on the coagulation of blood obtained from patients affected by hemophilia A. In the coagulating blood of these patients, the antithrombin/thrombin ratio was found to be markedly higher (about 44) than in normal individuals (about 4. 4). This high ratio was related to the low efficiency of thrombin-generating reactions induced by the factor VIII deficiency and to the high levels of free (not bound to serine proteases) antithrombin present in the hemophilic serum (antithrombin concentration was the same in normal and hemophilic plasma). The elevated concentration of free antithrombin in hemophiliacs was primarily a consequence of a reduced consumption caused by the scarce availability in the hemophilic serum of factors Xa and IIa, which are serine proteases possessing strong binding affinity for antithrombin. Addition of SV-IV to coagulating hemophilic blood reduced markedly the serum antithrombin and thrombin-antithrombin complexes, normalizing, as a consequence, the clotting time and other coagulation parameters. Similar results were obtained by using appropriate concentration of factor VIII.

Antithrombin III↗

PubMed2000

Production of macromolecular activators of phagocytosis by lysed platelets.

Macromolecular activators of phagocytosis from platelets (MAPP: 1-MAPP and s-MAPP) are released from activated fresh platelets and enhance leukocyte phagocytosis via the Fcgamma receptors. In this study, production of MAPP was investigated in lysate of freeze-thawed stored platelets (PL). Incubation of PL and thrombin with precursors of MAPP (pre-MAPP: pre-1-MAPP and pre-s-MAPP) produced 1-MAPP and s-MAPP, whereas products released from stored platelets by stimulation with thrombin or collagen did not produce MAPP after incubation with pre-MAPP. The action of thrombin in MAPP formation with PL and pre-MAPP was inhibited by antithrombin III and heparin, and sequential incubation studies indicated that the key site of action of thrombin was on a component of PL. Other serine proteases such as trypsin could be substituted for thrombin in this reaction, whereas the action of thrombin was specific when whole platelets were used instead of PL. Gel filtration of PL before and after treatment with thrombin suggested that a macromolecule in PL (PMA-I) is digested by thrombin and liberates a 700 to 800 Da substance (PMA-II) which converts pre-MAPP to MAPP.

Antithrombin III↗

PubMed2000

Extracellular granzyme A, complexed to proteoglycans, is protected against inactivation by protease inhibitors.

Granzyme A (GrA) and B (GrB) together with perforin are the main constituents of cytotoxic granules of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. The cytotoxic proteins are released to deliver a lethal hit during contact between the CTL or NK cell and target cell. With the use of an enzyme-linked immunosorbent assay for antigenic levels, we showed in a recent study that plasma of patients with activated CTLs and NK cells contain elevated levels of extracellular GrA. In this study, we determined the form and proteolytic capacity of this extracellular GrA detected in plasma. With the use of various assays, we show that part of the extracellular GrA circulates in the mature conformation and is bound to proteoglycans that protect it against inactivation by protease inhibitors, such as antithrombin III and alpha-2-macroglobulin, whereas another part of GrA circulates as a complex with antithrombin III. Finally, with the use of a novel assay for active GrA, we demonstrate that some plasma samples with high levels of extracellular GrA contain active GrA. These results suggest that various forms of extracellular GrA occur in vivo and that the regulation of GrA activity may be modified by proteoglycans. These data support the notion that granzymes may exert extracellular functions distant from the site of CTL or NK cell interaction with their target cells. (Blood. 2000;95:1465-1472)

Antithrombin III↗